Protein kinase c as a target for the treatment of respiratory syncytial virus
AssigneeUniversity of South Florida
InventorsSHYAM S. MOHAPATRA, HOMERO GABRIEL VERGARA
Life of this patent
Estimating the term…
Abstract
The subject invention concerns a method of inhibiting respiratory syncytial virus (RSV) infection in a patient by decreasing the endogenous protein kinase C (PKC) activity within the patient. Preferably, the preventative and therapeutic methods of the present invention involve administration of a PKC inhibitor. The present inventor has determined that decreasing normal endogenous PKC activity is inhibitory to RSV infection of human cells. The subject invention also pertains to pharmaceutical compositions containing a PKC inhibitor and a pharmaceutically acceptable carrier.
Claims15
A method of inhibiting a respiratory syncytial virus (RSV) infection in a mammal by decreasing the endogenous protein kinase C (PKC) activity within the mammal.
Dependencies are inferred from the claim text.